Colon cancer

Biomarkers identify aggressive Tumors

The blood test can help with the difficult decision of whether early-stage patients should recieve chemotherapy.
pixabay

Early-stage colon cancer patients could benefit in the future from  specific genetic tests that forecast their prognosis and help them make  the right decision regarding chemotherapy.

Two of the biomarkers involved are the MACC1 gene, high levels of which promote aggressive tumor growth and the development of metastasis, and a defective DNA mismatch repair (dMMR) system, which plays a role in tumor formation. Life expectancy is longer for patients with dMMR tumors and with low MACC1 gene activity.

The blood test can indicate whether there is a higher risk of the tumor returning or metastasizing. It helps with the difficult decision of whether early-stage patients should receive chemotherapy.

Ulrike Stein

Blood tests can help predict chemotherapy success

In recent years, scientists have successfully identified genetic subtypes of malignant colon tumors, all of which carry a different prognosis for how the disease will develop. Up to 15 percent of these malignant tumors, for example, exhibit defective DNA repair mechanisms – known as DNA mismatch repair deficiency or dMMR. Another important biomarker is the gene MACC1 (metastasis-associated in colon cancer 1), which was identified by Ulrike Stein and her colleagues at MDC in 2009. There is now a patented blood test for MACC1 detection.

The five-year survival rate for patients with stage I-III colon cancer who exhibit low levels of MACC1 lies at 80 percent – in comparison to just 15 percent for patients with high MACC1 levels. “The blood test can indicate whether there is a higher risk of the tumor returning or metastasizing,” says Stein. “It helps with the difficult decision of whether early-stage patients should receive chemotherapy.” This now also includes patients in stage II of the disease with impaired DNA repair mechanisms.


Source: Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft

28.07.2017

Read all latest stories

Related articles

CancerSEEK

Single blood test screens for 8 cancer types

Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer. The test, called CancerSEEK, is…

CRC-report shows urgent need for action

Limited public and political awareness of colorectal cancer (CRC), few formal screenings programms, delayed access to treatment - the first cross-country report on the management and funding of…

Hematopoietic Stem Cells

What keeps our blood in balance

Blood is the juice of life, as while circulating through the body it delivers vital substances such as oxygen and nutrients to cells and tissues. Chemotherapy, radiotherapy and blood loss in general…

Related products

Research use only (RUO)

Eppendorf - Mastercycler nexus X2

Eppendorf AG

Research use only (RUO)

Shimadzu - CLAM-2000

Shimadzu Europa GmbH